Australian regenerative medicine company Orthocell is teaming up with Johnson & Johnson’s DePuy Synthes Products to carry out trials evaluating Ortho-ATI® (autologous tenocyte implantation) therapy for regenerating degenerate tendons and ligaments. A multicenter study in Australia is expected to start during Q1 2017, led by Professor Allan Wang, at the University of Western Australia. Professor Wang is current president of the Shoulder and Elbow Society of Australia. “This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology,” commented Paul Anderson, Orthocell’s managing director.
Ortho-ATI is an autologous cell therapy, which involves expanding patient’s own own healthy tendon cells in the laboratory and injecting them back into the damaged tendon. Orthocell claims the product is the first autologous cell therapy for tendon and ligament repair and regeneration that has been licensed in the Australia, New Zealand, the U.S., Europe, China, and Japan. The treatment is already available in Australia and New Zealand for treating tendon injuries in patients who still have symptoms after conservative treatment options, such as exercise programs or corticosteroid injections.
Orthocell has separately developed and started commercialization of Ortho-ACI® (autologous chondrocyte implantation), an autologous chondrocyte cell product for treating damaged cartilage tissue. The firm’s CelGro® collagen scaffold platform has been developed for applications in tissue reconstruction and repair.